184 related articles for article (PubMed ID: 22164306)
1. The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.
Borriello A; Caldarelli I; Basile MA; Bencivenga D; Tramontano A; Perrotta S; Della Ragione F; Oliva A
PLoS One; 2011; 6(12):e28555. PubMed ID: 22164306
[TBL] [Abstract][Full Text] [Related]
2. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.
Id Boufker H; Lagneaux L; Najar M; Piccart M; Ghanem G; Body JJ; Journé F
BMC Cancer; 2010 Jun; 10():298. PubMed ID: 20565769
[TBL] [Abstract][Full Text] [Related]
3. Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors.
Tibullo D; Barbagallo I; Giallongo C; La Cava P; Branca A; Conticello C; Stagno F; Chiarenza A; Palumbo GA; Di Raimondo F
Hematol Oncol; 2012 Mar; 30(1):27-33. PubMed ID: 21544849
[TBL] [Abstract][Full Text] [Related]
4. Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells.
Rickard DJ; Wang FL; Rodriguez-Rojas AM; Wu Z; Trice WJ; Hoffman SJ; Votta B; Stroup GB; Kumar S; Nuttall ME
Bone; 2006 Dec; 39(6):1361-72. PubMed ID: 16904389
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.
Garcia-Gomez A; Ocio EM; Crusoe E; Santamaria C; Hernández-Campo P; Blanco JF; Sanchez-Guijo FM; Hernández-Iglesias T; Briñón JG; Fisac-Herrero RM; Lee FY; Pandiella A; San Miguel JF; Garayoa M
PLoS One; 2012; 7(4):e34914. PubMed ID: 22539950
[TBL] [Abstract][Full Text] [Related]
6. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
[TBL] [Abstract][Full Text] [Related]
7. 3,5-dicaffeoyl‑epi-quinic acid from Atriplex gmelinii enhances the osteoblast differentiation of bone marrow-derived human mesenchymal stromal cells via WnT/BMP signaling and suppresses adipocyte differentiation via AMPK activation.
Karadeniz F; Oh JH; Lee JI; Seo Y; Kong CS
Phytomedicine; 2020 Jun; 71():153225. PubMed ID: 32464299
[TBL] [Abstract][Full Text] [Related]
8. Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.
Jönsson S; Hjorth-Hansen H; Olsson B; Wadenvik H; Sundan A; Standal T
Leukemia; 2010 Jul; 24(7):1357-9. PubMed ID: 20485368
[No Abstract] [Full Text] [Related]
9. Oxysterols regulate differentiation of mesenchymal stem cells: pro-bone and anti-fat.
Kha HT; Basseri B; Shouhed D; Richardson J; Tetradis S; Hahn TJ; Parhami F
J Bone Miner Res; 2004 May; 19(5):830-40. PubMed ID: 15068507
[TBL] [Abstract][Full Text] [Related]
10. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
11. Effect of zinc ion on the osteogenic and adipogenic differentiation of mouse primary bone marrow stromal cells and the adipocytic trans-differentiation of mouse primary osteoblasts.
Wang T; Zhang JC; Chen Y; Xiao PG; Yang MS
J Trace Elem Med Biol; 2007; 21(2):84-91. PubMed ID: 17499147
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of osteoblastic and adipocytic differentiation potential with age and osteoporosis in human marrow stromal cell cultures.
Justesen J; Stenderup K; Eriksen EF; Kassem M
Calcif Tissue Int; 2002 Jul; 71(1):36-44. PubMed ID: 12200657
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
[TBL] [Abstract][Full Text] [Related]
14. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Cassuto O; Dufies M; Jacquel A; Robert G; Ginet C; Dubois A; Hamouda A; Puissant A; Luciano F; Karsenti JM; Legros L; Cassuto JP; Lenain P; Auberger P
Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
[TBL] [Abstract][Full Text] [Related]
15. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.
Fei F; Stoddart S; Müschen M; Kim YM; Groffen J; Heisterkamp N
Leukemia; 2010 Apr; 24(4):813-20. PubMed ID: 20111071
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol mimics insulin activity in the adipogenic commitment of human bone marrow mesenchymal stromal cells.
Caldarelli I; Speranza MC; Bencivenga D; Tramontano A; Borgia A; Pirozzi AV; Perrotta S; Oliva A; Della Ragione F; Borriello A
Int J Biochem Cell Biol; 2015 Mar; 60():60-72. PubMed ID: 25562512
[TBL] [Abstract][Full Text] [Related]
17. Glycogen synthase kinase-3α/β inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage.
Gambardella A; Nagaraju CK; O'Shea PJ; Mohanty ST; Kottam L; Pilling J; Sullivan M; Djerbi M; Koopmann W; Croucher PI; Bellantuono I
J Bone Miner Res; 2011 Apr; 26(4):811-21. PubMed ID: 20939016
[TBL] [Abstract][Full Text] [Related]
18. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Lee YC; Huang CF; Murshed M; Chu K; Araujo JC; Ye X; deCrombrugghe B; Yu-Lee LY; Gallick GE; Lin SH
Oncogene; 2010 Jun; 29(22):3196-207. PubMed ID: 20228840
[TBL] [Abstract][Full Text] [Related]
19. Adipogenic RNAs are transferred in osteoblasts via bone marrow adipocytes-derived extracellular vesicles (EVs).
Martin PJ; Haren N; Ghali O; Clabaut A; Chauveau C; Hardouin P; Broux O
BMC Cell Biol; 2015 Mar; 16():10. PubMed ID: 25887582
[TBL] [Abstract][Full Text] [Related]
20. 20(S)-hydroxycholesterol inhibits PPARgamma expression and adipogenic differentiation of bone marrow stromal cells through a hedgehog-dependent mechanism.
Kim WK; Meliton V; Amantea CM; Hahn TJ; Parhami F
J Bone Miner Res; 2007 Nov; 22(11):1711-9. PubMed ID: 17638575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
